New Battle In “Gendicine” Gene Therapy Patent War Begins
This article was originally published in PharmAsia News
Executive Summary
A new battle in the Gendicine gene therapy patent war recently began, but this time in an American courtroom
|
A new battle in the Gendicine gene therapy patent war recently began, but this time in an American courtroom. Pope Investments registered a case against Benda Pharmaceutical Mar. 31, calling for its liquidation and receivership due to insolvency. Benda owns a controlling stake in SiBiono, the company founded by the originiator of Gendicine, the world's first approved gene therapy treatment. If Pope ends up taking over Benda, it would then own both Gendicine and Advexin , another gene therapy product. Zhaohui Peng, creator of Gendicine , hopes that if Pope wins the case, control of both products would result in faster development. (Click Here For More - Chinese Language) "Gene Therapy Drug 'Gendicine' Re-Opens Curtain On Gene Therapy Battle"- news.163.com (4.13.10) |